Viewing nowCombinationLobahai Tablet 10/160 Milligrams
Rosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.

MFDS item code 202009007 · Approved 2020.12.18 · Insurance code 671706740
Treats hypertension and heart failure, improves hyperlipidemia, and reduces the risk of atherosclerosis, cardiovascular disease, and death
This medication is used for patients who require simultaneous treatment with valsartan and rosuvastatin. Valsartan helps treat essential hypertension and heart failure, as well as reducing the risk of mortality following myocardial infarction. It is particularly useful for heart failure patients who have shown intolerance to ACE inhibitors. Rosuvastatin regulates cholesterol levels in patients with hypercholesterolemia and dyslipidemia, and is effective in slowing the progression of atherosclerosis. Additionally, it is used to reduce the risk of stroke, myocardial infarction, and adverse outcomes after vascular interventions in patients at high risk for cardiovascular disease. Therefore, this medication aids in the treatment of patients with both hypertension and dyslipidemia.
This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect occurs gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be administered concomitantly. If further reduction in blood pressure is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose may be increased according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for patients with creatinine clearance of 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer this medicine to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, the medicines may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause severe damage to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential should use appropriate contraceptive methods and avoid taking the medication during pregnancy. It is advisable not to use this medication in patients with severe liver impairment or specific liver diseases, and in patients with severe renal impairment. Patients with musculoskeletal diseases or a high risk of myopathy should carefully monitor for symptoms such as myalgia or weakness while taking this medication. Caution is advised in elderly patients, patients with hyperkalemia, and patients with mild liver dysfunction; dosage adjustments and careful monitoring of condition are required. This medication lowers blood pressure, and hypotension symptoms may occur when starting use, so dizziness or fainting should be watched for. Regular liver function tests and muscle enzyme tests should be conducted to detect abnormal reactions early. There may be interactions when taken with other medications, so it is essential to inform the physician or pharmacist of any ongoing medication. Caution is particularly warranted if taken with potassium-sparing diuretics or potassium supplements, as blood potassium levels may increase dangerously. If muscle pain, muscle weakness, dizziness, severe fatigue, or other symptoms occur, notify healthcare personnel immediately, and consider discontinuation if necessary. This medication has not established safety and efficacy in children and adolescents, so it should generally not be used. In cases of overdose, severe hypotension or altered consciousness may occur; therefore, the prescribed dosage must be adhered to, and if any unusual symptoms occur, medical assistance should be sought immediately. This medication should be stored out of the reach of children and should not be transferred to another container.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver amino transferase, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory infection, edema, insomnia, erythema, decreased libido, vertigo, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, colicky pain, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, drowsiness, atrial fibrillation, vomiting, constipation, dry mouth, decreased appetite, lethargy, vascular edema, erythema, itching, serum sickness, vasculitis, syncope, epistaxis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, decreased hemoglobin, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, jaundice, Stevens-Johnson syndrome, urticaria, myalgia, myopathy, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and general symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia gravis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a closed container that blocks light, and it is recommended to keep it at a temperature between 1 to 30 degrees Celsius at room temperature. Storing it this way will help maintain the medication's efficacy over a long period.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP)*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.